{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095451","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.451296+00:00","generated_at":"2026-05-31T10:01:54.939375+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Clearside Biomedical Q2 net loss narrows to $7.6M; Phase 2b wet AMD trial on track for late Q3 data","bullets":["Net loss of $7.6M ($0.10/sh) vs $9.1M ($0.15/sh) in Q2 2023; license revenue $90,000.","Phase 2b ODYSSEY topline data for wet AMD expected late Q3 2024; no drug-related SAEs observed.","Cash and investments total $29.4M; company expects operations funded into Q3 2025.","Arctic Vision reports positive Phase 3 ARCATUS results; NDAs accepted in Australia and Singapore.","Tony Gibney appointed to Board; Dr. Glenn Yiu added to Scientific Advisory Board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095451","json":"https://secwatch.observer/filing/0000950170-24-095451.json","markdown":"https://secwatch.observer/filing/0000950170-24-095451.md","text":"https://secwatch.observer/filing/0000950170-24-095451.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017024095451/0000950170-24-095451-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017024095451/clsd-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:01:54.939375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}